Estrella Immunopharma
ESLA
7 hedge funds and large institutions have $143K invested in Estrella Immunopharma in 2023 Q4 according to their latest regulatory filings, with 6 funds opening new positions, increasing their positions, reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
133% more funds holding
Funds holding: 3 → 7 (+4)
12.79% less ownership
Funds ownership: 13.16% → 0.37% (-13%)
95% less capital invested
Capital invested by funds: $2.96M → $143K (-$2.82M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$85K |
| 2 |
ASM
ATW SPAC Management
New York
|
+$60.5K |
| 3 |
HHGC
Hunting Hill Global Capital
New York
|
+$32.3K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$955 |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$458 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCAM
Owl Creek Asset Management
New York
|
-$2.68M |
| 2 |
Jane Street
New York
|
-$192K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Geode Capital Management
Boston,
Massachusetts
| $63K | +$85K | +56,215 | New |
|
|
ASM
2
ATW SPAC Management
New York
| $44.4K | +$60.5K | +40,000 | New |
|
|
HHGC
3
Hunting Hill Global Capital
New York
| $23.7K | +$32.3K | +21,358 | New |
|
|
MCP
4
Maso Capital Partners
Hong Kong
| $11K | – | – | – |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $702 | +$955 | +632 | New |
|
|
6
UBS Group
Zurich,
Switzerland
| $336 | +$458 | +303 | New |
|
7
Wells Fargo
San Francisco,
California
| $81 | +$110 | +73 | New |
|
|
OCAM
8
Owl Creek Asset Management
New York
| – | -$2.68M | -255,000 | Closed |
|
|
9
Jane Street
New York
| – | -$192K | -20,505 | Closed |
|
ESLA Hedge Fund Activity: Q4 2023 in Review
7 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q4 2023, worth a combined $143K — down 95% from $2.96M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ESLA positions and 2 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Geode Capital Management, opening a new position worth an estimated $85K. The largest seller was Owl Creek Asset Management, exiting entirely with an estimated $2.68M sold.
- 7 institutional investors held Estrella Immunopharma (ESLA) as of Q4 2023, up from 3 in Q3 2023.
- Funds reported $143K of Estrella Immunopharma stock for Q4 2023, down 95% quarter-over-quarter.
- 6 funds opened new Estrella Immunopharma positions in Q4 2023 and 2 closed out, a net change of +4 holders.
- The largest Estrella Immunopharma buyer in Q4 2023 was Geode Capital Management, an estimated $85K added.
- The largest Estrella Immunopharma seller in Q4 2023 was Owl Creek Asset Management, an estimated $2.68M sold.
Based on aggregated 13F filings for Q4 2023.